Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down?

We reviewed Clostridioides difficile-positive patients discharged on fidaxomicin after local adoption of 2021 C. difficile infection (CDI) guidelines. From 14 June to 3 October 2021, 80% (12/15) had copayments of $0-$35 and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.

The impact of the pharmacist on continuity of care during transitions of care: A systematic review.

OBJECTIVES: To evaluate programs that provide pharmacy-led continuity of care services and to assess their effectiveness in improving patient outcomes. DATA SOURCES: Three databases were used to conduct the article search and assess relevant articles: PubMed (Medline), Cinahl, and Web of Science. STUDY SELECTION: Articles that included prospective measurement with defined clinical outcomes of the impact of including a pharmacist in discharge planning and continuity of care after a hospitalization were included in the review. Articles were limited to those available in English, conducted within the United States, and including humans. DATA EXTRACTION: Relevant articles from the full database collections through April 2017. RESULTS: Readmission rates were the most common primary outcome evaluated. Other primary outcomes included medication adherence, medication error identification and reduction, and patient satisfaction. Although the data has shown that pharmacists play a crucial role by promoting medication adherence and providing effective medication reconciliation, this systematic review did not result in identifying any one pharmacist intervention to be the most effective in improving continuity of care. CONCLUSION: There is both a need and an opportunity for research that supports best practices in providing continuity of care during transitions of care.